Atara Biotherapeutics Investors Face Deadline for Lead Plaintiff Role

Kirby McInerney LLP reminds investors of May 22, 2026 deadline to seek lead plaintiff status in securities class action lawsuit.

Apr. 17, 2026 at 9:35pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of legal documents, a calculator, and a gavel arranged elegantly on a clean, monochromatic background, conceptually representing the abstract concepts of corporate litigation, financial loss, and judicial decision-making.A securities class action lawsuit alleges Atara Biotherapeutics misled investors about its drug candidate, leading to significant stock declines.NYC Today

Kirby McInerney LLP is reminding investors in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) that they have until May 22, 2026 to seek the role of lead plaintiff in a pending federal securities class action lawsuit. The lawsuit alleges that Atara made misleading statements about the regulatory prospects of its tabelecleucel drug candidate, which led to significant stock price declines when the FDA issued complete response letters regarding the drug's approval.

Why it matters

The lead plaintiff in a securities class action oversees the litigation on behalf of the class and can influence key decisions like litigation strategy and settlement. Courts regularly appoint individual investors, not just institutions, as lead plaintiffs. This case highlights the importance for investors to act quickly to protect their rights and interests.

The details

The lawsuit alleges that Atara made misleading statements about tabelecleucel's regulatory prospects, including that (i) manufacturing issues and deficiencies in the ALLELE study made FDA approval unlikely, (ii) the manufacturing issues also subjected Atara to heightened regulatory scrutiny and jeopardized its clinical trials, and (iii) these issues would have a significant negative impact on Atara's business. The stock price declined significantly after the FDA issued complete response letters regarding the tabelecleucel BLA in January 2025 and January 2026.

  • The lawsuit covers the period from May 20, 2024 through January 9, 2026.
  • Atara received a Complete Response Letter from the FDA regarding the tabelecleucel BLA on January 16, 2025.
  • The FDA placed a clinical hold on Atara's active Investigational New Drug applications on January 21, 2025.
  • Atara received another Complete Response Letter regarding the tabelecleucel BLA on January 12, 2026.
  • The deadline for investors to seek lead plaintiff status is May 22, 2026.

The players

Kirby McInerney LLP

A New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Atara Biotherapeutics, Inc.

A biopharmaceutical company developing novel immunotherapies for patients with cancer and autoimmune diseases.

Got photos? Submit your photos here. ›

What they’re saying

“If you purchased or otherwise acquired Atara securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights or interests.”

— Lauren Molinaro, Attorney, Kirby McInerney LLP

What’s next

The judge in the case will decide on May 22, 2026 whether to appoint a lead plaintiff to oversee the litigation on behalf of the class.

The takeaway

This case highlights the importance for investors to act quickly to protect their rights and interests in securities class actions. The lead plaintiff role can significantly influence the outcome of the litigation, so Atara investors with substantial losses should consider applying before the May 22, 2026 deadline.